Who may be eligible for the Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial trial?

Inclusion Criteria: * Male or Female, age 45 years and over. * Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including 1. Vertical supranuclear gaze palsy. 2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years. * Access to the internet and webcam for virtual visits. * Presence of a caregiver. Exclusion Criteria: * Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer. * Significant metabolic or uncontrolled medical comorbidity. * Regular use of typical anti-cholinergic drugs. * Women of child-bearing potential, or who are pregnant and/or nursing. * Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory. * Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.

ClinicalTrials.gov record NCT07863180

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Oct 10, 2026

Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeInterventionalA study in which researchers assign participants to one or more interventions, such as a drug, procedure, device, behavioural programme or other approach, to measure their effects.

PhasePhase 1/2A study that combines safety and dose-finding (phase 1) with a first look at whether the treatment has an effect (phase 2).

Age45 years old and older

SexAll

LocationUnited States

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This randomized, double-masked Phase 1b/2 trial tests a dietary supplement called tributyrin taken three times daily for about 90 days versus placebo. It focuses on safety and tolerability and also assesses whether the supplement regimen and virtual visit approach are feasible for people with PSP and related disorders. Participation uses virtual visits and a caregiver is required per the registry.

What it is studying. The study tests whether taking oral tributyrin (500 mg three times a day for ~90 days) is safe and tolerable compared with placebo in people with PSP, Parkinson disease, or MSA, and whether a similar supplementation plan and virtual testing approach is feasible.

What the researchers hope to learn. Measure tolerability (dropout rate) and safety (serious adverse events) of tributyrin; evaluate feasibility of this supplementation regimen and virtual testing for people with PSP.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Drug: Tributyrin
Placebo

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Male or Female, age 45 years and over.
Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including
Vertical supranuclear gaze palsy.
Repeated unprovoked falls OR tendency to fall on the pull test within 3 years.
Access to the internet and webcam for virtual visits.
Presence of a caregiver.

Exclusion criteria

Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer.
Significant metabolic or uncontrolled medical comorbidity.
Regular use of typical anti-cholinergic drugs.
Women of child-bearing potential, or who are pregnant and/or nursing.
Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.
Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.

Study description and what participation involves

The study's detailed description, as published on ClinicalTrials.gov.

Detailed description from the registry

This is a sub-study of NCT07154511.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

If you join, you will be randomly assigned to take either 500 mg tributyrin or a matching placebo three times daily for about 90 days (±7 days). Visits and assessments are done virtually (internet webcam); the record refers to assessments through Visit 7, approximately day 90. The study is double-masked, and safety (serious adverse events) and tolerability (dropouts) are tracked up to Visit 7. The registry requires that participants have a caregiver and access to the internet and a webcam; the record does not list other on-study procedures or routine tests.

How the study is structured. Interventional, randomized, parallel-group, double-masked Phase 1/2 study. Participants are assigned to either tributyrin (500 mg TID) or matching placebo for 90 days (±7 days). The trial uses virtual visits (the registry requires internet and webcam access) and measures tolerability by dropout rate and safety by serious adverse events through approximately day 90.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

Some participants receive a placebo. How is that decided, and what happens for placebo-group participants when the study ends?
This is an early-phase study, mainly about safety and dose. What is already known about this treatment?
The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on progressive supranuclear palsy

This trial is also listed on this site under multiple system atrophy.

Clinical trials45 trials listed for progressive supranuclear palsyEvery trial the registry lists for progressive supranuclear palsy, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in progressive supranuclear palsy researchLatest monthly update: September 2026. Includes: PSP vs Parkinsons. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: September 2026 (estimated)
Primary completion: May 2027 (estimated)
Study completion: May 2027 (estimated)
Target enrollment: 15 participants (estimated)
Last updated on registry: Oct 7, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Prabesh Kanel
Collaborators: Farmer Family Foundation

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Nathan Alexander 📞 734-998-8422 ✉ natealex@med.umich.edu
Robert Vangel, BSc 📞 734-936-1168 ✉ rvangel@med.umich.edu

Participating sites (1)

Domino's FarmsRecruiting
Ann Arbor, Michigan, 48105 · United States
- Nathan Alexander · 734-998-8422 · natealex@med.umich.edu
- Robert Vangel, BSc · 734-936-1168 · rvangel@med.umich.edu
- Prabesh Kanel, PhD
- Nicolaas Bohnen, MD, PhD

Terms used on this page · explanations by MedicalUpdates.ai

Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials